BioMarin Exceeds Q4 Expectations, Eyes 2025 Growth

BioMarin Pharmaceutical reported impressive fourth-quarter results, with adjusted earnings per share of $0.92, surpassing analyst expectations of $0.73 and marking an 88% increase from the previous year. Revenue for the quarter was $747.3 million, a 16% rise year-over-year, driven by strong sales of the drug Voxzogo, which contributed $208 million, up 42%. The company has provided an optimistic outlook for 2025, expecting revenue between $3.1 billion and $3.2 billion, with adjusted earnings per share forecasted at $4.20 to $4.40. BioMarin's strategic expansions and product developments, particularly in its enzyme therapies and global market presence, underpin its growth prospects. CEO Alexander Hardy highlighted ongoing efforts to broaden the patient reach for their products, especially Voxzogo, as part of their enhanced corporate strategy. Despite a slight underperformance in stock price compared to the market, BioMarin's consistent earnings surprises suggest robust future performance.